壞死性小腸結腸炎市場規模、佔有率和成長分析：按治療方法、嚴重程度、最終用戶和地區分類－2026-2033年產業預測

2024 年全球壞死性小腸結腸炎市值為 36 億美元，預計到 2025 年將成長至 37.4 億美元，到 2033 年將成長至 55 億美元，在預測期（2026-2033 年）內複合年成長率為 3.92%。

壞死性小腸結腸炎 (NEOC) 的市場分析表明，在早產率上升和新生兒腸道疾病意識增強的推動下，預計該市場將呈現強勁成長。先進診斷技術的引入和基於微生物組的療法的進步顯著促進了藥物銷售的成長。生物標記診斷、益生菌、生物製藥和微創手術的日益普及進一步推動了市場擴張。對微生物組研究、精準醫療和疾病早期檢測的投資正在改善臨床療效並降低疾病嚴重程度。此外，對新生兒護理和合作研究的日益重視也創造了新的市場機會。然而，高昂的治療費用、已通過核准療法有限、嚴格的監管以及診斷的複雜性等挑戰可能會在可預見的未來阻礙市場滲透。

全球壞死性小腸結腸炎 (NEC) 市場按治療類型、嚴重程度、最終用戶和地區進行細分。依治療類型分類，市場分為「腸道休息和減壓療法」、「抗生素療法」、「手術干預」和「益生菌補充療法」。依嚴重程度分類，市場分為疑似、確診和晚期NEC。依最終用戶分類，市場分為新生兒加護病房(NICU)、兒童醫院及專科兒童手術中心。依地區分類，市場分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

全球壞死性小腸結腸炎市場成長要素

早產率的不斷上升要求新生兒醫療保健機構給予更多關注和專業護理，從而導致對預防壞死性小腸結腸炎 (NEC) 產品的需求日益成長。隨著醫療專業人員對該疾病及其嚴重影響的認知不斷加深，醫院也擴大採用實證管理方案。同時，倡導團體強調早期診斷和早期療育的關鍵性。這些趨勢是推動創新解決方案開發的主要動力，並鼓勵製造商進入市場，共同促進了全球 NEC 市場的強勁成長。這些因素共同凸顯了對有效護理產品的迫切需求。

全球壞死性小腸結腸炎市場的限制因素

由於新生兒加護病房(NICU) 數量有限，全球壞死性小腸結腸炎 (NEC) 市場面臨嚴峻挑戰。這些 NICU 需要具備早期發現和治療 NEC 所需的專業知識和技能。設施的匱乏阻礙了醫護人員採用先進的診斷和治療方法。因此，資源短缺成為產品製造商的障礙，導致這些地區的市場進入潛力較低。此外，早產兒轉診至更先進的醫療中心的困難也加劇了這個問題，限制了 NEC 相關治療領域的市場成長和創新。

壞死性小腸結腸炎的全球市場趨勢

受分子譜分析和即時影像技術進步的推動，全球壞死性小腸結腸炎市場正朝著更精準的診斷方向顯著轉變。這些創新工具能夠實現疾病的早期發現，使醫院能夠實施有效的監測方案和個人化的營養管理。這些改進不僅提升了患者照護，也最佳化了新生兒加護病房（NICU）的資源利用。隨著這些技術在全球醫療機構的日益普及，預計該市場將迎來強勁成長，促進積極主動的管理模式，並改善受壞死性小腸結腸炎影響的脆弱新生兒的整體治療效果。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢

全球壞死性小腸結腸炎市場規模：依治療類型分類

• 腸道休息和減壓療法
• 抗生素治療
• 手術介入
• 益生菌補充療法

全球壞死性小腸結腸炎市場規模：依嚴重程度分期

• NEC疑似病例
• 已確認的NEC
• 進行性小腸結腸炎

全球壞死性小腸結腸炎市場規模：依最終用戶分類

• 新生兒加護病房
• 兒童醫院
• 兒童外科專科中心

全球壞死性小腸結腸炎市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要公司2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要公司的完整公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要公司簡介

• Mead Johnson Nutrition Company
• Abbott Nutrition International
• Prolacta Bioscience Inc
• Angel Biotechnology Holdings
• Infant Bacterial Therapeutics AB
• Medela AG
• Nestle Health Science SA
• Danone Nutricia Research
• Astarte Medical Partners Inc
• Baxter International Inc
• Fresenius Kabi AG
• B Braun Melsungen AG
• Perrigo Company plc
• Humanigen Inc
• Deerfield Management Company
• Protaryx Biosciences Ltd
• Biomerica Inc
• Evolve BioSystems Inc
• ByHeart Inc
• Gerber Products Company

結論與建議

Global Necrotizing Enterocolitis Market size was valued at USD 3.6 Billion in 2024 and is poised to grow from USD 3.74 Billion in 2025 to USD 5.5 Billion by 2033, growing at a CAGR of 3.92% during the forecast period (2026-2033).

Market insights for necrotizing enterocolitis indicate robust growth driven by the rising prevalence of preterm births and heightened awareness of neonatal intestinal disorders. The adoption of advanced diagnostic technologies and improvements in microbiome-based therapies are contributing significantly to sales of treatments. The increasing use of biomarker-based diagnostics, probiotics, biologics, and minimally invasive surgical options further fuels market expansion. Investments in microbiome research, precision medicine, and early disease detection are enhancing clinical outcomes and reducing disease severity. Additionally, a growing focus on neonatal care and collaborative research is creating new market opportunities. However, challenges such as high treatment costs, limited approved therapies, stringent regulations, and complexities in diagnosis may impede market penetration in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Necrotizing Enterocolitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Necrotizing Enterocolitis Market Segments Analysis

Global necrotizing enterocolitis market is segmented by treatment type, severity stage, end user, and region. Based on treatment type, the market is segmented into bowel rest and decompression, antibiotic therapy, surgical intervention, and probiotic supplementation. Based on severity stage, the market is segmented into suspected NEC, Definite NEC, and advanced NEC. Based on end user, the market is segmented into neonatal intensive care units, pediatric hospitals, and specialty pediatric surgery centers. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Necrotizing Enterocolitis Market

The expanding population of preterm infants necessitates heightened attention and specialized care in neonatal settings, amplifying the need for products aimed at preventing necrotizing enterocolitis. As medical professionals enhance their understanding of the disease and its serious implications, hospitals are increasingly adopting evidence-based protocols for management. Simultaneously, advocacy organizations emphasize the critical importance of early diagnosis and intervention. These dynamics create a significant drive for the development of innovative solutions and encourage manufacturers to enter the market, collectively contributing to robust growth in the global necrotizing enterocolitis landscape. This convergence of factors underscores the urgency and demand for effective care products.

Restraints in the Global Necrotizing Enterocolitis Market

The Global Necrotizing Enterocolitis market faces significant challenges due to the limited availability of neonatal intensive care units equipped with the specialized expertise and technology required for the early detection and treatment of NEC. This lack of accessible facilities hinders medical professionals from employing advanced diagnostic and therapeutic approaches. Consequently, the scarcity of such resources presents obstacles for product manufacturers, as the potential for market adoption in these regions remains low. Moreover, the difficulty in transferring preterm infants to higher-level care centers further exacerbates the issue, creating barriers that restrict market growth and innovation in NEC-related treatments.

Market Trends of the Global Necrotizing Enterocolitis Market

The Global Necrotizing Enterocolitis market is witnessing a significant trend toward precision diagnostics, driven by advancements in molecular profiling and point-of-care imaging technologies. These innovative tools enable early detection of the condition, allowing hospitals to implement effective monitoring programs and tailored nutritional interventions. Such improvements enhance patient care while optimizing resource utilization in neonatal intensive care units. As healthcare facilities worldwide increasingly adopt these technologies, the market is likely to experience robust growth, fostering a culture of proactive management and improving overall outcomes for vulnerable neonates affected by necrotizing enterocolitis.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Necrotizing Enterocolitis Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Bowel Rest and Decompression
• Antibiotic Therapy
• Surgical Intervention
• Probiotic Supplementation

Global Necrotizing Enterocolitis Market Size by Severity Stage & CAGR (2026-2033)

• Market Overview
• Suspected NEC
• Definite NEC
• Advanced NEC

Global Necrotizing Enterocolitis Market Size by End User & CAGR (2026-2033)

• Market Overview
• Neonatal Intensive Care Units
• Pediatric Hospitals
• Specialty Pediatric Surgery Centers

Global Necrotizing Enterocolitis Market Size & CAGR (2026-2033)

• North America (Treatment Type, Severity Stage, End User)
  • US
  • Canada
• Europe (Treatment Type, Severity Stage, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Severity Stage, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Severity Stage, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Severity Stage, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Mead Johnson Nutrition Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Nutrition International
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Prolacta Bioscience Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Angel Biotechnology Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Infant Bacterial Therapeutics AB
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medela AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Health Science SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danone Nutricia Research
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astarte Medical Partners Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius Kabi AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Perrigo Company plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Humanigen Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Deerfield Management Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protaryx Biosciences Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biomerica Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evolve BioSystems Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ByHeart Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gerber Products Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations